Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
Subscribe To Our Newsletter & Stay Updated
